Overview

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in patients who have already received therapy. The safety of this drug combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Rituximab
Thalidomide